Shares of this little company are up +100% in the past month.

After reporting record fourth-quarter revenue last week, shares didn't move. Why? Because investors aren't paying attention to this microcap...yet.

This development-stage biotech company expects good news on its liver cancer treatment within the month. And FDA approval could come next year.

This undervalued high yielder has just begun its post-bear comeback.

This unique little company pays a stable double-digit yield and trades at bargain levels. Still, few are paying attention.

Up +10% so far this year while the S&P has been negative, this company's current yield is now about double its historical average. Even better, the company has hiked its dividend fourteen times in the past fifteen years, for a total increase of +1000%.

A small pharmaceutical company with a big partner has a therapy that must be making cigarette company executives crave a smoke. Investors can now get in on the ground floor of this potentially historic drug.

This unknown business-development company has increased its dividend +33% per year since it went public in 2004.

The federal government leases 97% of this company's property.

This little company has been accelerating revenues all year and now yields 5.25%.